Laverock Therapeutics is pioneering a novel approach to gene silencing that leverages the cell's intrinsic gene regulatory mechanisms. Their technology focuses on the use of naturally occurring microRNAs (miRNAs) to conditionally silence genes in a manner that is programmable, tunable, stable, and specific. This innovative method allows for precise control over gene expression, enabling the targeting of the right genes in the right cells at the right time. The platform has demonstrated its versatility across multiple target genes and cell types, showcasing the ability to silence more than one gene simultaneously, which broadens its therapeutic applications significantly.

The company is actively applying its gene silencing technology to develop advanced therapies aimed at treating serious diseases, particularly in the fields of oncology and genetic disorders. Laverock's approach not only enhances the safety and efficacy of these therapies but also opens avenues for addressing various high-impact therapeutic areas through strategic partnerships. Their ongoing research and development efforts are supported by a robust industrialized platform that increases throughput and efficiency in product development, positioning Laverock Therapeutics as a leader in the next generation of advanced therapies.

United Kingdom

Laverock was founded around the core Gene Editing induced Gene Silencing Platform – a step-change in RNAi technology. We fundamentally believe it unlocks the development of next-generation therapeutics through its unique and differentiated properties. We are actively developing a pipeline of GEiGS enabled ex vivo cell therapies, as well in vivo therapeutic approaches.

Laverock Therapeutics

Company Details